| Literature DB >> 20588285 |
Abstract
Current treatment for antibody-mediated kidney transplant rejection is inadequate. Tillou and colleagues administered recombinant C1 inhibitor to block complement activation to prevent antibody-initiated injury in sensitized baboon recipients of kidney allografts. These early but encouraging results support further testing of the safety and efficacy of complement inhibition as part of a comprehensive strategy to treat this disease, both in animal models and ultimately in humans.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20588285 DOI： 10.1038/ki.2010.80
Source DB: PubMed Journal: Kidney Int ISSN： 0085-2538 Impact factor: 10.612